Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.41 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060315 | 0.84 | ADORA2A (0.38) | ADORA2AADORA1TLR7ADORA2BTMIGD3 | |
| SCHEMBL10309722 | 0.81 | PDE4A (0.43) | ADORA2AADORA1TLR7ADORA2BTMIGD3 | |
| SCHEMBL13233223 | 0.77 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BTMIGD3ADORA3 | |
| SCHEMBL2060338 | 0.77 | TLR7 (0.52) | TLR7 | |
| SCHEMBL10309738 | 0.77 | TLR7 (0.47) | ADORA1TLR7 | |
| SCHEMBL2060449 | 0.76 | TLR7 (0.51) | ADORA2AADORA1TLR7ADORA2BTMIGD3 | |
| SCHEMBL6153574 | 0.76 | TLR7 (0.63) | ADORA2AADORA1TLR7ADORA2BTMIGD3 | |
| SCHEMBL19378277 | 0.75 | TLR7 (0.43) | ADORA1TLR7ADORA3 | |
| SCHEMBL10174470 | 0.74 | TSHR (0.40) | ADORA2AADORA1TLR7 | |
| SCHEMBL2060341 | 0.73 | ADORA2A (0.45) | ADORA2AADORA1TLR7ADORA2BTMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, HRH4, P2RY10 | ADORA2A 4/4885ADORA1 1/4885TLR7 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.